-
India hopes 'unique idea' will save athletes from cabin fever
-
PU Prime Launches Australian Operations under ASIC Licence
-
UK asserts 'unshakeable' Falklands commitment after Milei presses claim
-
Night-owl Zverev goes distance to advance as upsets rock US Open
-
How a Dostoevsky novella took TikTok by storm
-
Marathon man Zverev goes distance again to reach US Open third round
-
Zverev goes the distance again to reach US Open third round
-
US study tests psilocybin to fight cancer side effects
-
German AfD's love for Simson mopeds dismays Jewish family behind brand
-
Italy's Meloni throws party to celebrate record in power
-
Two trapped tunnel workers rescued in Nepal 'miracle'
-
After heatwaves, will EU pivot back to the climate fight?
-
Ex-Pakistan coach Gillespie tells Javed 'look in the mirror' over sackings
-
South Korean football referee faces hearing over 'period' insult
-
Monfils falls to Tien in US Open in Grand Slam farewell
-
Toulouse eye Top 14 history after 'difficult' summer
-
Arsenal brace for Chelsea test as Spurs seek spark
-
Springboks and All Blacks seek series lead after war of words
-
Efficient Rybakina reaches US Open third round
-
Bundesliga brings the band back together in Premier League's shadow
-
Taiwan boxer Lin considered 'graceful exit' after Paris Games gold
-
Asian stocks rally as traders pare rate bets ahead of jobs data
-
'I miss my home': Cambodians displaced by conflict start over
-
War-bruised Myanmar finds relief in bareknuckle bloodsport
-
Ailing Auger-Aliassime falls at US Open as Swiatek, Osaka and Gauff advance
-
Gauff downs Badosa to reach US Open third round
-
Tesla launches self-driving 'Cybercab' in Texas
-
New Zealand approves use of party drug MDMA to treat trauma
-
'Wallace & Gromit' creators turn 50 with spook-tacular Shaun yarn
-
Westerners test their mettle at World Nomad Games in Kyrgyzstan
-
New York's Muslims reclaim their city after 9/11 backlash
-
Gauff cruises into US Open third round
-
Premier League transfer windfall a lifeline for ailing French clubs
-
Kyrgios gets month ban for cocaine, enters treatment programme
-
Chile protesters see shades of Pinochet in new security plan
-
Colombian judge bans strikes on guerrillas if minors are present
-
Carreras reverts to fullback as Argentina change four for Australia Test
-
Khachanov shocks ailing Auger-Aliassime, Swiatek and Osaka advance at US Open
-
Wilson back to lead Australia as Kiss rotates team for Argentina
-
Lone juror blocking verdict in US mother's child murder trial: defense
-
Yen surges on new intervention talk, US stocks rally
-
'Kinda chic' - Williams sisters set to launch US Open doubles bid
-
Japan's Ueda fires Lille top of Ligue 1 on debut
-
Volkswagen says cutting 100,000 jobs by end of decade
-
Arsenal chief executive reveals 'dynasty' ambition
-
Russia slaps curfew on charity director over army criticism
-
Spanish PM says no 'solid proof' Morocco planned migrant rush
-
Ailing Auger-Aliassime upset by Khachanov at US Open
-
Iran war is not a war, US VP Vance says
-
Richarlison omitted from Tottenham's Premier League squad
Grief and outrage in Gambia over cough syrup deaths
When Wuri Bailo Keita's two-year-old daughter Fatoumatta developed a fever, he took her to hospital where she was diagnosed with malaria and sent home with a prescription for a paracetamol syrup.
Less than a week later she was dead.
The infant is just one of 69 Gambian children to die of acute kidney failure since July in a series of cases linked to four Indian-made cough syrups.
The widening scandal has highlighted flaws in the tiny West African nation's healthcare system, in turn raising questions about potential loopholes in world pharmaceutical trade.
"She could not eat anything and she was oozing blood from her mouth and nose", Keita, a 33-year-old carwash attendant, told AFP, recounting his daughter's suffering.
"At some point, I was praying for God to take her life."
President Adama Barrow made a nationwide address on Saturday after the police launched an inquiry and health authorities were told to suspend the import licence of a suspected company.
Barrow also promised to update drugs-related laws and praised the work of the health ministry in preventing further deaths.
But fear and anger are mounting, and the death toll is still rising.
"President Barrow should sack the health minister, but instead of sacking him, he was praising the minister," said Keita, the grieving father.
"We want justice for these children."
Social media has been swamped by criticism of the healthcare system and by photos of the children who have died, most of whom were aged under five.
"It's time for the government to step up and stop these products," Mariama Kuyateh, a 30-year-old mother who lost her son Musa in September, told AFP.
"If they don't, and other syrups enter the country, it will be terrible."
- No test lab -
The deaths were catapulted to global prominence last Wednesday when the UN's World Health Organization (WHO) issued an alert over four syrups made by Maiden Pharmaceuticals of India.
Lab tests found "unacceptable amounts" of diethylene glycol and ethylene glycol, the WHO said.
The toxic impact from these substances includes "acute kidney injury which may lead to death," the agency said.
The Gambian health authorities, after launching their own investigation in July, on September 23 ordered a recall of all medicines containing paracetamol or promethazine syrup.
They have cited E.coli bacteria as a possible cause of the deaths.
India's health ministry said late Thursday it had been informed of the WHO's findings last month and was awaiting the results of its own lab tests on the four drugs.
Maiden Pharmaceuticals was not licensed to distribute the four products in India and had only manufactured and exported them to The Gambia, it said.
"It is a usual practice that the importing country tests these imported products on quality parameters, and satisfies itself as to the quality of the products," the ministry said.
But The Gambia has no national laboratory to test for drug quality and food safety -- a lack that Barrow on Saturday vowed to redress.
Maiden Pharmaceuticals did not respond to AFP requests for comment after the WHO alert.
- 'Failed miserably' -
Domestic critics accuse Barrow of having failed to protect the public and standing by watchdogs who should have been sacked.
The opposition United Democratic Party (UDP) criticised Barrow's "five-minute address" to a "traumatised nation left to wonder what other pharmaceuticals are on the market that may be fake or unsafe for use."
Nancy Jallow, of an NGO called Global Bridges, said she was appalled that top officials such as Health Minister Ahmadou Lamin Samateh and the head of the Medicines Control Agency, Markieu Janneh Kaira, were still in their jobs.
"We signed a social contract with Adama Barrow and his number one role is to protect the most vulnerable, and he has failed miserably," she told AFP.
She also called for a total halt to pharmaceutical imports "until Gambia's government can build a facility that can test medications."
Others voices, including the Gambia Bar Association, have insisted that the inquiry be conducted by independent experts.
- Weak healthcare -
Behind the political row is the reality of a country deep in poverty lacking many of the safeguards that elsewhere are taken for granted.
The Gambia is the smallest country in continental Africa, and nearly half of its population lives below the poverty line, according to the World Bank.
The country ranks a mere 174th out of 191 countries on the UN Human Development Index.
Its already weak health institutions were hit hard by Covid, with a 2020 UN assessment saying the pandemic had "exposed the shortcomings in the nation's healthcare system".
The UN flagged limited expertise, a shortage of basic equipment and a chronic lack of health professionals.
According to World Bank data, The Gambia in 2019 had just 0.1 physicians per 1,000 people -- less than a twentieth of the numbers in Canada.
The Gambia's under-five mortality rate is 49.4 deaths per 1,000 live births, according to UNICEF, compared to 3.7 deaths in Germany and 4.4 in France.
F.Ferraz--PC